- Construction has started on a new biologics facility in Dundalk, Ireland.
- The facility will have a capacity of 48,000L fed-batch and 6,000L perfusion.
- It is supported by the Irish Government through IDA Ireland.
Project Overview
WuXi Biologics has commenced construction of a new biologics drug substance manufacturing facility in Dundalk, Ireland. This site is located on the Industrial Development Authority’s (IDA) greenfield site in Mullagharlin, Co. Louth. It marks the company's first facility outside of China, supported by the Irish Government through IDA Ireland.
Facility Features
The facility is designed to incorporate both traditional fed-batch or perfusion processes and continuous bioprocessing. This next-generation manufacturing technology will be implemented globally for the first time at this 26-hectare campus. Upon completion, the facility will have a total capacity of 48,000L fed-batch and 6,000L perfusion, making it one of the largest facilities using single-use bioreactors worldwide.
Strategic Importance
This development is a significant step in WuXi Biologics' strategy to expand its global biomanufacturing network. The facility aims to ensure high-quality biologics manufacturing and a robust supply chain to benefit patients globally. The project also involves collaboration with local partners to establish a state-of-the-art biomanufacturing facility, setting a benchmark for the global biotech community.
